SHANGHAI, March 24 /PRNewswire-Asia/ -- WuXi AppTec (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced the addition of three key senior professionals.
Dr. Brian J. Xu has joined WuXi AppTec as Vice President of Toxicology and
Head of the Safety Evaluation Center at Suzhou, reporting to Dr. Ge Li,
Chairman and Chief Executive Officer. Dr. Xu is an American Board Certified
Toxicologist (DABT) and had worked previously in Merck, Roche, Schering-Plough
and Enzon. Dr. Xu received his Ph.D. from
Dr. Yang-Dar Yuan has joined the company as Vice President of Operation
and Head of Pathology of the Safety Evaluation Center, reporting to Dr. Brian
Xu. Dr. Yuan is a member of American College of Veterinary Pathologists (ACVP),
a member of the American College of Laboratory Animal Medicine and an American
Board Certified Toxicologist (DABT). He brings more than 30 years of rich
experiences in preclinical safety assessment and drug development. Dr. Yuan
had worked previously in Upjohn, Pfizer, Allergan and Vitae Pharmaceutical. Dr.
Yuan received a D.V.M. from National Taiwan University and a Ph.D. in
Veterinary Pathology from
Mr. Robert Coldreck has joined the company as Head of GLP (Good Laboratory
Practice) QA (Quality Assurance). Mr. Coldreck had previously worked in
Novartis, most recently as Director of Laboratory and Preclinical Quality
Assurance-North America and Asia. He brings more than 30 years of rich
experience in GLP quality assurance. Mr. Coldreck received his B.S. in Biology
"I am delighted to welcome Brian, Yang-Dar and Bob to our management team to lead our preclinical services," said Dr. Li. "With their rich experience and knowledge in GLP preclinical studies and their strong leadership in respective fields, WuXi continues to build a world-class preclinical service platform to serve our customers' demands."
About WuXi AppTec and WuXi PharmaTech
WuXi PharmaTech (NYSE: WX) is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .
For more information, please contact: Sherry Shao WuXi PharmaTech (Cayman) Inc. Tel: +86-21-5046-4002 Email: firstname.lastname@example.org
|SOURCE WuXi PharmaTech (Cayman) Inc.|
Copyright©2009 PR Newswire.
All rights reserved